SEARCH

SEARCH BY CITATION

References

  • Ariga T., Kobayashi K., Hasegawa A., Kiso M., Ishida H. and Miyatake T. (2001) Characterization of high-affinity binding between gangliosides and amyloid β-protein. Arch. Biochem. Biophys. 388, 225230.
  • Avdulov N. A., Chochina S. V., Igbavboa U., O'Hare E. O., Schroeder F., Cleary J. P. and Wood W. G. (1997) Lipid binding to amyloid β-peptide aggregates: preferential binding of cholesterol as compared to phosphatidylcholine and fatty acids. J. Neurochem. 68, 20862091.
  • Baenziger J. E., Morris M. L., Darsaut T. E. and Ryan S. E. (2000) Effect of membrane lipid composition on the conformational equilibria of the nicotinic acetylcholine receptor. J. Biol. Chem. 275, 777784.
  • Bales K. R., Verina T., Du Dodel R. C. Y., Altstiel L., Bender M., Hyslop P., Johnstone E. M., Cummins D. J., Piccardo P., Ghetti B. and Paul S. M. (1997) Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet. 17, 263264.
  • Chochina S. V., Avdulov N. A., Igbavboa U., Cleary J. P., O'Hare E. O. and Wood W. G. (2001) Amyloid β-peptide (1–40) increases neuronal membrane fluidity. Role of cholesterol and brain region. J. Lipid Res. 42, 12921297.
  • Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Haines J. L. and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in the late onset familial disease. Science 261, 921923.
  • Cory A. H., Owen T. C., Barltrop J. A. and Cory J. G. (1991) Use of an aqueous soluble tetrazolium assay for cell-growth assays in culture. Cancer Commun. 3, 207212.
  • Curtain C. C., Ali F., Volitakis I., Cherny R. A., Norton R. S., Beyreuther K., Barrow C. J., Masters C. L., Bush A. I. and Barnham K. J. (2001) Alzheimer's disease amyloid β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276, 2046620473.
  • Czech C., Forstl H., Hentschel F., Monning U., Besthorn C., Geigerkabisch C., Sattel H., Masters C. and Beyruether K. (1994) Apolipoprotein E-4 gene dose in clinically diagnosed Alzhiemer's disease: prevalence, plasma cholesterol levels and cerebrovascular change. Eur. Arch. Psychiatry Clin. Neurosci. 243, 291292.
  • Eckert G. P., Cairns N. J., Maras A., Gattaz W. F. and Muller W. E. (2000) Cholesterol modulates the membrane-disordering effects of β-amyloid peptides in the hippocampus specific changes in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11, 181186.
  • Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller. P., Runz H., Kuhl S., Bertsch T., von Bergmann. K., Hennerici M., Beyreuther K. and Hartmann T. (2001) Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 58565861.
  • Frears E. R., Stephens D. J., Walters C. E., Davies H. and Austen B. M. (1999) The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport 10, 16991705.
  • Friedhoff L. T., Cullen E. I., Geoghagen N. S. and Buxbaum J. D. (2001) Treatment with controlled-release lovastatin decreases serum concentrations of human β-amyloid (Aβ) peptide. Int. J. Neuropsychopharmacol. 4, 127130.
  • Glenner G. G. and Wong C. W. (1984) Alzheimers disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885890.
  • Hartmann T. (2001) Cholesterol, Aβ and Alzheimer's disease. Trends Neurosci. 24, S45S48.
  • Hertel C., Terzi E., Hauser N., Jakob-Rotne R., Seelig J. and Kemp J. A. (1997) Inhibition of the electrostatic interaction between β-amyloid peptide and membranes prevents β-amyloid-induced toxicity. Proc. Natl Acad. Sci. USA 94, 94129416.
  • Hubbard A. L., Wall D. A. and Ma A. (1983) Isolation of rat hepatocyte plasma membranes. I. Presence of three major domains. J. Cell Biol. 96, 217229.
  • Jakobisiak M., Bruno S., Skierski J. S. and Darzynliewicz Z. (1991) Cell cycle-specific effects of lovastatin. Proc. Natl Acad. Sci. USA 88, 36283632.
  • Jarrett J. T. and Lansbury P. T. Jr (1993) Seeding ‘one-dimensional crystallization’ of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 10551058.
  • Ji S. R., Wu Y. and Sui S. F. (2002) Cholesterol is an important factor affecting the membrane insertion of β-amyloid peptide (Aβ1–40), which may potentially inhibit the fibril formation. J. Biol. Chem. in press:.
  • Jick H., Zornberg G. L., Jick S. S. and Drachman D. A. (2000) Statins and the risk of dementia. Lancet 356, 16271631.
  • Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K. and Müller-Hill B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733736.
  • Klunk W. E., Jacob R. F. and Mason R. P. (1999) Quantifying amyloid β-peptide (Aβ) aggregation using the Congo red-Aβ (CR-Aβ) spectrophotometric assay. Anal. Biochem. 266, 6676.
  • Kojro E., Gimpl G., Lammick S., Marz W. and Fahrenholz F. (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl Acad. Sci. USA 98, 58155820.
  • Kremer J. J., Pallitto M. M., Sklansky D. J. and Murphy R. M. (2000) Correlation of β-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity in membranes. Biochemistry 39, 1030910318.
  • Kremer J. J., Sklansky D. J. and Murphy R. M. (2001) Profile of changes in lipid bilayer structure caused by β-amyloid pepide. Biochemistry 40, 85638471.
  • Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L., Wals P., Zhang C., Finch C. E., Krafft G. A. and Klein W. L. (1998) Diffusable, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 64486453.
  • Mahfoud R., Garmy N., Maresca M., Yahi N., Puigserver A. and Fantini J. (2002) Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins. J. Biol. Chem. 277, 1129211296.
  • Masters C. L., Simms G., Weinman N. A., Multahup G., McDonald B. L. and Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer's disease and Down's syndrome. Proc. Natl Acad. Sci. USA 82, 42454249.
  • Mizuno T., Haass C., Michikawa M. and Yanagisawa K. (1998) Cholesterol dependant generation of a unique amyloid β-protein from apically missorted amyloid precursor protein in MDCK cells. Biochim. Biophys. Acta 1373, 119130.
  • Mozsolits H., Wirth H. J., Werkmeister J. and Aguilar M. I. (2001) Analysis of antimicrobial peptide interactions with hybrid bilayer membrane systems using surface plasmon resonance. Biochim. Biophys. Acta 1512, 6476.
  • Nunan J. and Small D. H. (2000) Regulation of APP cleavage by α-, β- and γ-secretases. FEBS Lett. 483, 610.
  • Pike C. J., Walencewicz A. J., Glabe C. G. and Cotman C. W. (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311314.
  • Podlinsny M. B., Walsh D. M., Amarante P., Ostaszewski B. L., Stimson E. R., Maggio J. E., Teplow D. B. and Selkoe D. J. (1998) Oligomizeration of endogenous and synthetic amyloid β-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 37, 36023611.
  • Price J. L., Davis P. B., Morris J. C. and White D. L. (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. Aging 12, 295312.
  • Refolo L. M., Pappolla J., Malester M. A., LaFrancois B., Thomas-Bryant T., Wang R., Tint G. S., Sambamurti K. and Duff K. E. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321331.
  • Refolo L. M., Pappolla M. A., LaFrancois J., Malester B., Schmidt S. D., Thomas-Bryant T., Tint G. S., Wang R., Mercken M., Petanceska S. S. and Duff K. E. (2001) A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8, 890899.
  • Roher A. E., Kuo Y. M., Kokjohn K. M., Emmerling M. R. and Gracon S. (1999) Amyloid and lipids in the pathology of Alzheimer's disease. Amyloid 6, 136145.
  • Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandervert C., Walker S., Wogulis M., Yednock T., Games D. and Seubert P. (1999) Immunization with amyloid-β attenuates Alzheimer's disease like pathology in the PDAPP mouse. Nature 400, 173177.
  • Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D. and Younkin S. (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is incorporated in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864870.
  • Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. and Simons K. (1998) Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 95, 64606464.
  • Small D. H. and McLean C. A. (1999) Alzheimer's disease and the amyloid β protein: What is the role of amyloid? J. Neurochem. 73, 443449.
  • Small D. H., Mok S. S. and Bornstein J. C. (2001) Alzheirmer's disease and Aβ toxicity: from top to bottom. Nat. Rev. Neurosci. 2, 595598.
  • Sparks D. L., Scheff S. W., Hunsaker J. C., Liu H. and Gross D. R. (1994) Induction of Alzheimer-like β amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 8894.
  • Sugahara M., Uragami M., Yan X. and Regen S. L. (2001) The structural role of cholesterol in biological membranes. J. Am. Chem. Soc. 123, 79397940.
  • Valdez-Gonzalez T., Inagawa J. and Ido T. (2001) Neuropeptides interact with glycolipid receptors: a surface plasmon resonance study. Peptides 22, 10991106.
  • Vinters H. V. (1987) Cerebral amyloid angiopathy: a critical review. Stroke 18, 311324.
  • Wang S. S. S., Rymer D. L. and Good T. A. (2001) Reduction in cholesterol and sialic acid content protects cells from the toxic effects of β-amyloid peptides. J. Biol. Chem. 276, 4202742034.
  • Waschuk S. A., Elton E. A., Darabie A. A., Fraser P. E. and McLaurin J. A. (2001) Cellular membrane composition defines Aβ lipid interactions. J. Biol. Chem. 276, 3356133568.
  • Wolozin B., Kellman W., Ruosseau P., Celesia G. G. and Siegel G. (2000) Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 14391443.
  • Zhou Y. and Richardson J. S. (1996) Cholesterol protects PC12 cells from β amyloid-induced calcium disordering and cytotoxicity. Neuroreport 7, 24872490.